Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
45 participants
INTERVENTIONAL
2018-10-01
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
No intervention
No interventions assigned to this group
Candesartan
Candesartan 8 mg/day
Candesartan
Candesartan 8 mg/day
Ramipril
Ramipril 1.25 mg/day
Ramipril
ramipril 1.25 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Candesartan
Candesartan 8 mg/day
Ramipril
ramipril 1.25 mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Thalassemia
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sherief Abd-Elsalam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gamal El-azab, Prof
Role: PRINCIPAL_INVESTIGATOR
Clinical pharmacy Department- Tanta University
Tarek Mostafa, Prof
Role: STUDY_DIRECTOR
Cardiology Department- Tanta University
Gamal Badra, Prof
Role: STUDY_CHAIR
National Hepatology Institute - Egypt
Abeer El-Motwally, Msc
Role: STUDY_CHAIR
Clinical pharmacy Department-Tanta University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Abeer Abd-Almohsen, Msc
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Mostafa TM, El-Azab GA, Badra GA, Abdelwahed AS, Elsayed AA. Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study. Curr Ther Res Clin Exp. 2021 Nov 12;95:100654. doi: 10.1016/j.curtheres.2021.100654. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
liver fibrosis
Identifier Type: -
Identifier Source: org_study_id